Internal Medicine, Hematology & Oncology · Grand Rapids, MI
NPI
1639179286
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
145 Michigan St NE Ste 3100
Grand Rapids, MI, 49503
Phone (616) 954-9800
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
51,942 services
Medicare patients, 2024
274
Average age 72
Drug cost, 2024
$3.8M
1,846 prescriptions
Company payments, 2025
$1,877
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thomas E Gribbin was code J1100 (injection, dexamethasone sodium phosphate, 1 mg), 524 times for 24 patients. In total Thomas E Gribbin billed 51,942 services in 149 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-03-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 524 | 24 | $0.09 | $46.52 |
| 85025 Blood Count | Office | 253 | 77 | $7.39 | $1,871 |
| 36415 Venipuncture Blood Collection | Office | 235 | 81 | $8.62 | $2,025 |
| 99214 Office E&M - Established | Office | 220 | 122 | $88.12 | $19K |
| 96413 Chemotherapy Administration | Office | 206 | 44 | $90.49 | $19K |
| 80053 Clinical Chemistry | Office | 196 | 63 | $10.24 | $2,006 |
| M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 142 | 35 | $71.08 | $10K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 132 | 19 | $4.22 | $557 |
| 96375 Injection Administration | Office | 128 | 32 | $10.73 | $1,374 |
| 99213 Office E&M - Established | Office | 94 | 73 | $56.90 | $5,348 |
| 99233 Hospital E&M - Subsequent | Facility | 62 | 19 | $83.36 | $5,168 |
| 84443 Clinical Chemistry | Office | 49 | 11 | $16.46 | $807 |
| 96415 Chemotherapy Administration | Office | 47 | 12 | $20.18 | $949 |
| 99215 Office E&M - Established | Office | 44 | 28 | $129.43 | $5,695 |
| 96372 Injection Administration | Office | 35 | 21 | $10.36 | $362 |
By year: 2022 $958K for 58,468 services; 2023 $1.3M for 60,202 services; 2024 $1.2M for 51,942 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 253 | 77 | $7.39 | $1,871 |
| 36415 Venipuncture Blood Collection | 235 | 81 | $8.62 | $2,025 |
| 80053 Clinical Chemistry | 196 | 63 | $10.24 | $2,006 |
| 84443 Clinical Chemistry | 49 | 11 | $16.46 | $807 |
| 85610 Clinical Chemistry | 15 | 15 | $4.20 | $63 |
| 82728 Clinical Chemistry | 14 | 11 | $13.36 | $187 |
| 82306 Clinical Chemistry | 12 | 12 | $29.01 | $348 |
Medicare prescription drug claims, 2024
In 2024, the drug Thomas E Gribbin prescribed most often to Medicare patients was Anastrozole, with 336 prescriptions and refills. In total Thomas E Gribbin wrote 1,846 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 336 | 922 | 112 | $13K |
| Tamoxifen Citrate Generic | 295 | 795 | 92 | $11K |
| Acyclovir Generic | 188 | 221 | 30 | $2,752 |
| Calquence Acalabrutinib Maleate | 85 | 85 | Under 11 | $1.2M |
| Exemestane Generic | 61 | 173 | 20 | $19K |
| Letrozole Generic | 60 | 144 | 18 | $2,979 |
| Hydroxyurea Generic | 49 | 106 | 13 | $2,639 |
| Prochlorperazine Maleate Generic | 49 | 49 | 34 | $633 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 46 | 48 | Under 11 | $73.11 |
| Nyvepria Pegfilgrastim-Apgf | 32 | 32 | Under 11 | $117K |
| Ondansetron Odt Ondansetron | 31 | 31 | 19 | $342 |
| Eliquis Apixaban | 30 | 34 | Under 11 | $19K |
| Prednisone Generic | 30 | 30 | Under 11 | $98.74 |
| Dexamethasone Generic | 27 | 39 | 13 | $482 |
| Venlafaxine Hcl Er Venlafaxine Hcl | 26 | 34 | Under 11 | $503 |
Brand drugs: 326 claims; generic drugs: 1,520 claims; opioid claims: 34.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thomas E Gribbin $1,877 ($1,877 in general payments such as food, travel and fees) from 25 companies. The largest payer was Novartis Pharmaceuticals Corporation with $298.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 15 | $298 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $234 |
| Merck Sharp & Dohme LLC MRK | 8 | $234 |
| GlaxoSmithKline, LLC. GSK | 12 | $201 |
| Geron Corporation GERN | 4 | $111 |
| Pfizer Inc. PFE | 11 | $105 |
| Genentech USA, Inc. ROG.SW | 3 | $77.77 |
| Genzyme Corporation SNY | 4 | $75.91 |
| BeOne Medicines USA, Inc. ONC | 3 | $74.88 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 2 | $54.28 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.